Content about VALENCIA

April 3, 2014

MannKind Corp. on Tuesday announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the Food and Drug Administration voted 13-to-1 to recommend that Afrezza (insulin human [rDNA origin]) inhalation powder be granted marketing approval by the FDA to improve glycemic control in adults with Type 1 diabetes and voted 14-to-0 to recommend that Afrezza be granted marketing approval by the FDA to improve glycemic control in adults with Type 2 diabetes.

VALENCIA, Calif. — MannKind Corp. on Tuesday announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the Food and Drug Administration voted 13-to-1 to recommend that Afrezza (insulin human [rDNA origin]) inhalation powder be granted marketing approval by the FDA to improve glycemic control in adults with Type 1 diabetes and voted 14-to-0 to recommend that Afrezza be granted marketing approval by the FDA to improve glycemic control in adults with Type 2 diabetes. 

December 6, 2012

Trigg Laboratories on Thursday announced they will help Sonny and Sharie Knight, owners of the Hillbilly Hot Dogs restaurant in West Virginia, celebrate 13 years of wedlock on Dec. 12.

VALENCIA, Calif. — Trigg Laboratories on Thursday announced they will help Sonny and Sharie Knight, owners of the Hillbilly Hot Dogs restaurant in West Virginia, celebrate 13 years of wedlock on Dec. 12. 

Featuring their brand Wet Personal Lubricants, Trigg Laboratories competed with many other candidates to host the 30th vow renewal for the couple. "Trigg Laboratories is so excited to host Sonny and Sharie as they renew their vow to love each other," stated Jennifer Martsolf, VP marketing at Trigg Laboratories. 

January 20, 2011

It seems that MannKind has experienced a setback with a drug designed to control hyperglycemia in Type 1 and Type 2 diabetes patients.

VALENCIA, Calif. — It seems that MannKind has experienced a setback with a drug designed to control hyperglycemia in Type 1 and Type 2 diabetes patients.

The Food and Drug Administration on Thursday issued a complete response letter to the drug maker regarding Afrezza (insulin human [rDNA origin]) inhalation powder. The regulatory agency requested that the company conduct two clinical trials, one in patients with Type 1 diabetes and one in patients with Type 2 diabetes, with its next-generation inhaler, to assure it works as effectively as MedTone, its predecessor.